May 29, 2026
iProgen Biotech out-licensed its Antibody Internalization Technologies to AOCera
Therapeutics Inc. (www.AOCera.com), headquartered in San Diego, USA. AOCera
Therapeutics is a biotechnology company developing precision medicines that use
antibody-oligonucleotide conjugate (AOC) technology to deliver RNA therapeutics
directly to specific tissues and cells. Its platform is designed to improve the targeted
delivery of siRNA, antisense oligonucleotides, and other nucleic acid therapies, with a
focus on treating genetic and other serious diseases while minimizing off-target effects.
